A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Phase IIa Study of Safety and Motor Function Restoration in Subjects Treated With SA4503 Following Acute Ischemic Stroke.
Latest Information Update: 21 Oct 2014
At a glance
- Drugs Cutamesine (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Ms Science
- 24 Jun 2009 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
- 01 Feb 2008 New trial record.